Rohto and Mitsui lead acquisition of Eu Yan Sang for $695M

The Japanese companies acquired an 86% stake in the company.

A consortium led by Japanese companies Rohto Pharmaceutical and Mitsui & Co. has acquired Singapore-based traditional Chinese medicine company Eu Yan Sang International (EYSI) for $695m.

The consortium acquired an 86% stake from Righteous Crane Holding (RCH).

RCH is an investment holding company owned by Tower Capital Asia subsidiary, Tower Capital TCM Holdings, and Temasek Holdings unit Blanca Investments.

“In 2016, we chose to partner with Tower Capital Asia due to their understanding of the Eu Yan Sang heritage and commitment to driving excellence. Tower Capital Asia, together with Temasek, was instrumental in elevating the EYSI brand, institutionalising operations, and establishing the foundation for our next chapter as a natural health and wellness brand," said Richard Eu, chairman of EYSI.

Follow the link for more news on

Acquisitions

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia